Figure 4From: Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsisEffects of differing bevacizumab treatment times on mortality in the murine models of sepsis. A, Delayed administration of Bev is protective in cecal ligation and puncture (CLP). Kaplan-Meier survival analysis following CLP in mice comparing the efficacy of pre- and post-surgical bevacizumab (Bev) treatment at various time intervals relative to the CLP control. Bev administration significantly enhanced survival relative to the CLP controls (P = 0.006 in the pre-treated group, and P = 0.033 in the 6 h post-treated group), except for mice in which Bev administration was delayed for 12 h (12 h delayed-treatment group, P = 0.062). B, Lethality from endotoxemia was diminished with delayed Bev administration, but not statistically significantly so.Back to article page